NCT06372652View on ClinicalTrials.gov

A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

October 10, 2024

Study Completion Date

December 6, 2024

Conditions
Acromegaly
Interventions
DRUG

TE-8214 - SAD

Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg

DRUG

Placebo

Single subcutaneous dose of matching placebo across the cohorts

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors

Lead Sponsor

Immunwork, Inc.
All Listed Sponsors
lead

Immunwork, Inc.

INDUSTRY